James McCloskey, MD
Medical Oncology · Hackensack, NJNPI 1992951149
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $2,192,184 of the $2,806,119 with a category attached, or 78.1%. It is spread thinly across 38 manufacturers, the largest accounting for just 16.5%. Among medical oncology clinicians in NJ with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 2,013 payments — averaging $1394.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Takeda Pharmaceuticals U.S.A., Inc.$463K
- GSK$258K
- E.r. Squibb & Sons, L.L.C.$256K
- Blueprint Medicines Corporation$224K
- Pharmaessentia USA Corporation$204K
- Bristol Myers Squibb$204K
- plus $1.2M from 32 others
Across 2,763 payments — averaging $5194.70 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Otsuka Pharmaceutical Co., Ltd.$2.3M
- Jazz Pharmaceuticals Inc.$1.5M
- Taiho Oncology, Inc.$1.5M
- Servier Bioinnovation$1.3M
- Servier Pharmaceuticals LLC$1.1M
- AbbVie$1.1M
- plus $5.6M from 22 others
What the payments were for
- Consulting fees$254,4649%
- Speaking & faculty fees$2,192,18478%
- Travel & lodging$325,20512%
- Food & beverage$32,6561%
- Education$1,6110%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,806,119 in reported general payments places this provider in the 95th percentile of 112 medical oncology providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JakafiRuxolitinib Phosphate | 148 | $2,626,332 |
| AyvakitAvapritinib | 33 | $1,098,865 |
| OjjaaraMomelotinib Dihydrochloride | 24 | $649,696 |
| InqoviDecitabine/Cedazuridine | 64 | $524,725 |
| PromactaEltrombopag Olamine | 19 | $516,529 |
| TasignaNilotinib Hcl | 30 | $460,712 |
| SprycelDasatinib | 54 | $447,615 |
| BosulifBosutinib | 33 | $433,764 |
| OnuregAzacitidine | 16 | $368,906 |
| IclusigPonatinib Hcl | 13 | $285,391 |
| BesremiRopeginterferon Alfa-2b-Njft | 11 | $185,820 |
| Imatinib Mesylate | 50 | $93,436 |
| VenclextaVenetoclax | 42 | $88,304 |
| Dasatinib | 12 | $72,645 |
| Posaconazole | 40 | $61,234 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Incyte CorporationJakafi | $145,612 | $2,626,332148 claims |
| Blueprint Medicines CorporationAyvakit | $223,658 | $1,098,86533 claims |
| NovartisPromacta, Tasigna | $50,460 | $977,24149 claims |
| E.r. Squibb & Sons, L.L.C.Sprycel, Onureg | $256,057 | $816,52170 claims |
| GSKOjjaara | $257,795 | $649,69624 claims |
| Taiho Oncology, Inc.Inqovi | $5,333 | $524,72564 claims |
| PfizerBosulif | $22,065 | $433,76433 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Iclusig | $462,893 | $285,39113 claims |
| Pharmaessentia USA CorporationBesremi | $204,325 | $185,82011 claims |
| AbbVieVenclexta | $31,120 | $88,30442 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 112 medical oncology providers in New Jersey.
Other medical oncology in Hackensack
- Jamie KoprivnikarHackensack$1.7M
- Andrew PecoraHackensack$1.2M
- David VesoleHackensack$726K
- Lori LeslieHackensack$665K
- Noa BiranHackensack$263K
- Robert AlterHackensack$232K
- Harry HarperHackensack$226K
- Tatyana FeldmanHackensack$193K
- David SiegelHackensack$171K
- Andrew IpHackensack$169K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.